Vorsetuzumab mafodotin

Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) directed to the protein CD70 designed for the treatment of cancer.[1] It is a humanized monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethyl auristatin F (MMAF), a cytotoxic agent.

Vorsetuzumab mafodotin
Monoclonal antibody
Type?
SourceHumanized (from mouse)
TargetCD70
Clinical data
Other namesSGN-75
ATC code
  • none
Legal status
Legal status
  • Discontinued
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC6476H10006N1726O2028S50(C49H78N6O11)3-5
Molar mass150 kg/mol

This drug was developed by Seattle Genetics, Inc. The drug completed phase I clinical trials for renal cell carcinoma,[2] but development was discontinued in 2013.[3] No reason was given but SG plan to start clinical trials of SGN-CD70A in 2014.[3]

References
  1. Statement On A Nonproprietary Name Adopted By The USAN Council: Vorsetuzumab Mafodotin, American Medical Association.
  2. Clinical trials for SGN-75 "Clinicaltrials.gov"
  3. Seattle Genetics Third Quarter 2013 Financial Report


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.